Merck stock slides amid strong selling pressure despite Phase 3 immunology trial update

Traders Union
All News
Companies
Merck slides 1.40% today

Highlights

MRK trades below short- and medium-term moving averages, indicating persistent selling pressure and a bearish technical outlook.
Momentum and oscillator readings confirm a weak trend with oversold signals, highlighting continued downside risk in the near term.
MRK is expected to consolidate between $112.00 and $117.50 next week, with further declines likely if support at $113.88 fails.

Downside pressure as MRK trades below short-term moving averages

MRK is trading at $114.02, below the SMA-20 ($118.05) and SMA-50 ($115.68), pointing to strong short- and medium-term selling pressure. The Ichimoku Kijun on D1 stands at $117.20, marking immediate resistance, while the SMA-200 at $105.39 remains a key long-term support. Near-term support is seen at the EMA-100 ($113.88), with key support at the SMA-200 ($105.39). Immediate resistance is set by the Kijun ($117.20), and key resistance aligns with the SMA-20 ($118.05).

Oversold momentum signals reinforce persistent weekly price weakness

Momentum signals remain weak as MACD on D1 is neutral at -0.18 and ADX posts a low reading of 12.88, reflecting a lack of trend strength. RSI (43.38) and CCI (-131.67) are both in oversold territory, joined by an oversold Stoch RSI and negative BBP (-2.22), highlighting persistent seller dominance. The Awesome Oscillator signals a strong sell, reinforcing downside momentum. MRK is trading at $114.02, down from $118.89 a week ago, reflecting a 4.10% decline. The price is positioned in the lower part of the weekly range and weekly volatility stands at 8.48%. This week's tone signals a steady decline from recent highs. In today's session, the stock is down 1.4%, underscoring continued downside pressure.

Further decline risk as upside probability remains minimal

For the upcoming week, MRK is expected to trade between $112.00 and $117.50, keeping within a realistic band close to the current price, given the recent volatility and the 52-week range of $76.66 to $125.14. Based on weekly MA and oscillator signals, there is a very low probability (less than 20%) of a sustained upward move, making further decline more likely in the near term. The baseline scenario sees MRK consolidating sideways between $112 and $117.50. A bullish scenario would require a decisive break above $117.20–$118.05 to open the path toward $121.25. Downside risk intensifies if the price breaks below near-term support at $113.88, with $112 and potentially $105.39 in focus.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that Merck exhibited strong bullish momentum and limited downside risk, with technical indicators favoring a cautiously optimistic outlook. As the current situation unfolds, traders should monitor shifts in market sentiment for any signs of renewed upside, while keeping a close watch on the next key resistance level to confirm the prevailing trend.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.